BRIEF published on 07/09/2024 at 08:15, 1 year 9 months ago Andera Partners Co-Leads €63 Million Series A for Biotech SciRhom Series A Financing Biopharmaceuticals Andera Partners Autoimmune Disorders SciRhom
PRESS RELEASE published on 07/09/2024 at 08:10, 1 year 9 months ago Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom to advance novel iRhom2 antibody therapy towards clinical proof-of-concept Andera Partners SciRhom Autoimmune Biotech Series A Round IRhom2 Antibody
BRIEF published on 03/14/2024 at 11:15, 2 years 1 month ago Andera Partners’ Portfolio Company Tubulis Secures €128 Million in Series B2 Financing Clinical Trials Andera Partners Tubulis Series B2 Financing ADC Development
PRESS RELEASE published on 03/14/2024 at 11:10, 2 years 1 month ago Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 financing to accelerate ADC pipeline development Andera Partners Tubulis €128 Million Series B2 ADC Pipeline Biotech Financing
BRIEF published on 03/14/2024 at 09:05, 2 years 1 month ago AstraZeneca Acquires Amolyt Pharma for up to $1.05 Billion Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Rare Diseases
PRESS RELEASE published on 03/14/2024 at 09:00, 2 years 1 month ago Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca Amolyt Pharma, a clinical-stage biopharmaceutical company specializing in therapeutic peptides, is being acquired by AstraZeneca for $1.05 billion. The transaction is expected to close in Q3 2024 Acquisition AstraZeneca Amolyt Pharma Therapeutic Peptides Rare Endocrine Diseases
PRESS RELEASE published on 05/15/2023 at 09:00, 2 years 11 months ago Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases
PRESS RELEASE published on 05/10/2023 at 09:00, 2 years 11 months ago Andera Partners appoints Stefan Keitel Senior Advisor DACH region further strengthening its presence in the German, Austrian and Swiss private equity markets
PRESS RELEASE published on 04/18/2023 at 09:15, 2 years 11 months ago Andera Partners co-leads a Series A extension round totalling € 47.75 million for radiopharmaceutical company Ariceum Therapeutics
PRESS RELEASE published on 04/13/2023 at 12:45, 3 years ago Andera Partners leads $48.5 Million Series A financing for medical device company BioVentrix®
Published on 04/17/2026 at 02:13, 3 hours 31 minutes ago CHAR Tech annonce l’acquisition projetée d’actifs de biocarbone au Québec, incluant un accord d’achat de 62 500 tonnes, une installation et de la propriété intellectuelle
Published on 04/17/2026 at 02:00, 3 hours 44 minutes ago UraniumX Announces Closing Of Final Tranche Of Non-Brokered Private Placement
Published on 04/16/2026 at 23:32, 6 hours 12 minutes ago Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale
Published on 04/16/2026 at 21:30, 8 hours 14 minutes ago Organto Foods Expands Financing Facilities with Rabobank
Published on 04/17/2026 at 04:55, 49 minutes ago Hyundai Mobis Develops Data-Driven Validation System to Dramatically Cut Testing Time for SDVs
Published on 04/16/2026 at 23:40, 6 hours 4 minutes ago Coventry Ranks #1 in 2025 Life Settlement League Table Report
Published on 04/16/2026 at 21:37, 8 hours 7 minutes ago Approval of the Offer Document concerning the voluntary tender offer for shares of NEXT RE SIIQ S.p.A.
Published on 04/16/2026 at 21:00, 8 hours 44 minutes ago Vizrt AI Keyer kills the green screen and creates virtual scenes in any environment
Published on 04/16/2026 at 20:35, 9 hours 9 minutes ago EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Published on 04/16/2026 at 18:02, 11 hours 42 minutes ago Covivio - Description of the share buy-back program authorized by the Combined Ordinary and Extraordinary Shareholders’ Meeting held on 16 April 2026
Published on 04/16/2026 at 17:54, 11 hours 50 minutes ago Aéroports de Paris S.A - March 2026 traffic figures
